CMES1 New Treatment Option for Acromegaly: Debate and Discussion on the Use of Oral Octreotide

Program: CMES Ancillary Events
Clinical Session
Saturday, April 2, 2016: 6:30 PM-9:00 PM
Grand Ballroom (The Westin)
Supported by an educational grant from Chiasma, Inc.

Registration is required for this session:

Learning Objectives:

Upon completing this activity, learners will be better able to:

  • Explain safety outcomes associated with use of different options, e.g., control of GH/IGF-I levels, amelioration of signs/symptoms, improved QoL, ease of administration
  • Educate patients in successful management of their disease given the complexities of everyday life
  • Understand and share latest clinical developments in treating patients with acromegaly
7:20 PM

Anne Klibanski, MD, Neuroendocrine Unit, Massachusetts General Hospital/Harvard Medical School, Boston, MA
Disclosure Not Provided: AK
7:25 PM

Anne Klibanski, MD, Neuroendocrine Unit, Massachusetts General Hospital/Harvard Medical School, Boston, MA
Disclosure Not Provided: AK
7:40 PM

Shlomo Melmed, MB, ChB, Academic Affairs Administration, Cedars-Sinai Medical Center, Los Angeles, CA
Disclosures:
SM: Scientific Board Member, chiasma, Investigator, Pfizer, Inc., Coinvestigator, Ipsen, Ad Hoc Consultant, Novartis Pharmaceuticals, Consultant, ISIS.
7:55 PM

Peter J. Trainer, MD, FRCP, The Christie NHS Foundation Trust, Manchester, United Kingdom
Disclosure Not Provided: PJT
8:10 PM

Anne Klibanski, MD, Neuroendocrine Unit, Massachusetts General Hospital/Harvard Medical School, Boston, MA
Disclosure Not Provided: AK
See more of: CMES Ancillary Events